SciELO - Scientific Electronic Library Online

 
vol.29 issue2Isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolated in patients with coexisting tuberculosis and Human Immunodeficiency Virus, Colombia 2010 - 2012TriBURTER: invention and perceptual validation of a portable device aimed to induce high- frequency vibration and respiratory muscle training in patients with respiratory diseases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Medicas UIS

Print version ISSN 0121-0319

Abstract

OCAMPO-KOHN, Catalina et al. Plasmapheresis in antibody-mediated renal allograft rejection. Experience of Pablo Tobon Uribe, Medellin, Colombia. Year 2005-2015. Medicas UIS [online]. 2016, vol.29, n.2, pp.41-48. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v29n2-2016004.

Background: antibody-mediated renal allograft rejection is a complication after kidney transplantation, and it has poor prognosis for graft survival. Plasmapheresis has been used with controversial results; few trials indicate a trend towards superior graft survival in patients receiving this treatment; however, the evidence remains weak. Objetive: the aim of this study was to describe the experience in treating Antibody-mediated renal allograft rejection with plasmapheresis in kidney transplant recipients. Methods: retrospective and descriptive study of the patients that underwent three to nine session of plasmapheresis as a treatment of severe Antibody-mediated renal allograft rejection in Pablo Tobón Uribe Hospital. Results: between August 2005 and June 2015, 769 patients underwent kidney transplantation at our institution; 26 patients received plasmapheresis as part of the treatment for Antibody-mediated renal allograft rejection. All patients received induction therapy. Maintenance therapy used was tacrolimus, mycophenolic acid and steroids in 80,8% of the patients and cyclosporine, micophenolic acid and steroids in 19,2%. Antibody mediated rejection had an early onset in 61,5% of the cases. At six and 12 months after therapy, 44% and 53,8% patients respectively were back on dialysis. Complications were reported in 53,8% of the patients (hypocalcaemia, hypotension and anaphylaxis). Conclusion: in this cohort, 50% of patients who received Plasmapheresis as therapy for severe Antibody-mediated renal allograft rejection presented loss graft after one year of follow up. It is necessary adding to this therapy new treatment alternatives, among them intravenous immunoglobulin, rituximab, eculizumab and bortezomib. MÉD.UIS. 2016;29(2):41-8.

Keywords : Plasmapheresis; Graft rejection; Graft Survival; Kidney transplantation.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License